Increased mRNA expression of collagen V gene in pulmonary fibrosis of systemic sclerosis. 2010

E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. erparra20003@yahoo.com.br

BACKGROUND Collagen V shows promise as an inducer of interstitial lung fibrosis in experimental systemic sclerosis (SSc). METHODS Remodelling of the pulmonary interstitium was evaluated based on the clinical data and open lung biopsies from 15 patients with SSc. Normal lung tissues obtained from eight individuals who died of traumatic injuries were used as control group. Immunofluorescence, immunohistochemistry, morphometry, tri-dimensional reconstruction and a real-time polymerase chain reaction were used to evaluate the quantity, structure and molecular chains of collagen V. The impact of these markers was tested on clinical data. RESULTS The main difference in collagen V content between SSc patients and the control group was an increased, abnormal and distorted fibre deposition in the alveolar septa and the pre-acinar artery wall. The lungs from SSc patients presented [alpha1(V)] and [alpha2(V)] mRNA chain expression increased, but [alpha2(V)] was proportionally increased compared with the control group. High levels of collagen V were inversely associated with vital capacity (r = -0.72; P = 0.002), forced vital capacity (r = -0.76; P < 0.001), forced expiratory volume in 1-s (r = -0.89; P < 0.001) and diffusing capacity for carbon monoxide (r = -0.62; P = 0.04). CONCLUSIONS Abnormal collagen V fibres are overproduced in lungs from SSc patients and may play an important role in the pathogenesis of the disease as this molecule regulates tissue collagen assembly. The aberrant histoarchitecture observed in SSc can be related to the overexpression of the [alpha2(V)] gene of unknown origin.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001706 Biopsy Removal and pathologic examination of specimens from the living body. Biopsies
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis

Related Publications

E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
December 1990, Arthritis and rheumatism,
E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
January 1995, Annals of internal medicine,
E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
November 2019, Experimental dermatology,
E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
January 1997, Pneumoftiziologia : revista Societatii Romane de Pneumoftiziologie,
E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
March 2011, Arthritis and rheumatism,
E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
November 2014, American journal of respiratory and critical care medicine,
E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
January 2012, Journal of thoracic imaging,
E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
December 2005, Annals of the rheumatic diseases,
E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
September 1991, Lancet (London, England),
E R Parra, and W R Teodoro, and J de Morais, and M L H Katayama, and R de Souza, and N H Yoshinari, and V L Capelozzi
November 1991, Lancet (London, England),
Copied contents to your clipboard!